EFFECTS OF HYDROXYCHLOROQUINE PLUS FAVIPIRAVIR TREATMENT ON THE CLINICAL COURSE AND BIOMARKERS IN HOSPITALIZED COVID-19 PATIENTS WITH PNEUMONIA

Simple item page
dc.authoridtetik, bora/0000-0001-7696-7785
dc.authoridKasapoglu, Umut Sabri/0000-0003-2869-9872
dc.authorwosidtetik, bora/AAA-8841-2021
dc.authorwosidKasapoglu, Umut Sabri/F-1786-2019
dc.contributor.authorDelen, Leman Acun
dc.contributor.authorGok, Abdullah
dc.contributor.authorKasapoglu, Umut Sabri
dc.contributor.authorCagasar, Ozlem
dc.contributor.authorGok, Zarife
dc.contributor.authorBerber, Nurcan
dc.contributor.authorDerya, Serdar
dc.date.accessioned2024-08-04T20:53:36Z
dc.date.available2024-08-04T20:53:36Z
dc.date.issued2022
dc.departmentİnönü Üniversitesien_US
dc.description.abstractBackground: The novel coronavirus disease 2019 (COVID-19) has a broad spectrum of clin-ical manifestations, the most common serious clinical manifestation of the coronavirus infection being pneumo-nia. Unfortunately, the optimal treatment approach is still uncertain. However, many studies have been conducted on the effectiveness of several medications in the treatment of COVID-19 infection. The aim of this study was to evaluate the effectiveness of the hydroxychloroquine (HCQ) + favipiravir (FAV) treatment regimen and HCQ alone by comparing the patient's clinical response and laboratory results on the fifth day of treatment in patients hospitalized due to COVID-19 infection.Patients and methods: This retrospective cohort study was conducted in Malatya Training and Research Hospital between March 2020 and July 2020. The study included 69 patients with confirmed COVID-19 with pneumonia. The patients were divided into 2 groups, those receiving HCQ alone and those receiving the HCQ + FAV combination.Results: A total of 69 patients were included in the study, and the mean age was 60.09 +/- 15.56 years. A statisti-cally significant decrease was observed in C-reactive protein (CRP) levels, at the end of the fifth day, in patients who received HCQ + FAV treatment (p=0.002), whereas there was no decrease in CRP levels in patients who received HCQ treatment alone. In addition, an increase in lymphocyte count and a better fever response was observed at the end of the fifth day in patients who received HCQ + FAV (p=0.008). However, there was no statistical difference between both treatment regimens in terms of hospital stay and treatment results (p=0.008, p=0.744, p=0.517).Conclusion: Although the combination of HCQ + FAV treatment was observed to be effective on CRP levels and fever response in patients with COVID-19 pneumonia, there was no difference in terms of hospital stay and discharge.en_US
dc.identifier.doi10.20471/acc.2022.61.03.05
dc.identifier.endpage411en_US
dc.identifier.issn0353-9466
dc.identifier.issn1333-9451
dc.identifier.issue3en_US
dc.identifier.pmid37492367en_US
dc.identifier.scopus2-s2.0-85152300729en_US
dc.identifier.scopusqualityQ3en_US
dc.identifier.startpage403en_US
dc.identifier.urihttps://doi.org/10.20471/acc.2022.61.03.05
dc.identifier.urihttps://hdl.handle.net/11616/101286
dc.identifier.volume61en_US
dc.identifier.wosWOS:000958104900005en_US
dc.identifier.wosqualityQ4en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherSestre Milosrdnice Univ Hospitalen_US
dc.relation.ispartofActa Clinica Croaticaen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectFavipiraviren_US
dc.subjecthydroxychloroquineen_US
dc.subjectCOVID-19en_US
dc.subjectSARS-COV-2en_US
dc.subjectpneumoniaen_US
dc.titleEFFECTS OF HYDROXYCHLOROQUINE PLUS FAVIPIRAVIR TREATMENT ON THE CLINICAL COURSE AND BIOMARKERS IN HOSPITALIZED COVID-19 PATIENTS WITH PNEUMONIAen_US
dc.typeArticleen_US

Files

Collections

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu

We collect and process your personal information for the following purposes: Authentication, Preferences, Acknowledgement and Statistics.
To learn more, please read our privacy policy.

Customize